New study checks allergy Pill's safety and symptom relief

NCT ID NCT05720455

Completed Symptom relief Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the safety and effectiveness of Allegra D (fexofenadine plus pseudoephedrine) in 203 people aged 12 and older with allergic rhinitis. Participants took the medication for up to 13 days, and researchers tracked side effects and symptom improvement using nasal and total symptom scores. The goal was to confirm the drug works well and is safe for this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHINITIS, ALLERGIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic rhinitis perennial allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHINITIS, ALLERGIC

Contacts and locations

Show contact details

Locations

Apex Hospital Private Limited

Jaipur, Rajasthan, 302017, India
Belagavi Institute of Medical science

Belagavi, Karnataka, 590001, India
Dr BR Ambedkar Medical College & Hospital

Bangalore, Karnataka, 560045, India
Misha ENT Hospital

Ahmedabad, Gujarat, 380008, India
Moti Lal Nehru Medical College

Allahābād, Uttar Pradesh, 211002, India
Nil Ratan Sircar Medical College

Kolkata, West Bengal, 700014, India
Pt B.D. Sharma, PGIMS

Rohtak, Haryana, 124001, India
Sahyadri super speciality hospital

Pune, Maharashtra, 411004, India
Silver Touch Multispecialty Hospital

Ahmedabad, Gujarat, 380015, India
Sum Ultimate Medicare

Bhubaneswar, Odisha, 751003, India
Swami Rama Himalayan University

Dehradun, Uttarakhand, 248140, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.